Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00059735
Other study ID # E7070-A001-206
Secondary ID
Status Completed
Phase Phase 2
First received May 5, 2003
Last updated February 29, 2008
Start date May 2002
Est. completion date December 2003

Study information

Verified date February 2008
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.


Description:

Renal Cell Carcinoma (RCC) accounts for approximately 2% of all cancers and its incidence is increasing with worldwide deaths of over 100,000 patients per year. About 50% of RCC patients have inoperable or metastatic disease that surgery cannot be performed on. RCC is also considered to be resistant to both radiotherapy and cytotoxic chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of E7070 by assessing progression free survival, tumor response rate, duration of response/stable disease, and survival time. E7070 will be administered as a single iv infusion over 60 minutes on Day 1 of each cycle. Patients will continue treatment with E7070 until they no longer have clinical benefit and have disease progression, or toxicity leads to patient withdrawal.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >=18 years old.

- Have histologically/cytologically confirmed clear cell RCC.

- Previously untreated or one prior treatment with immunotherapy (one prior treatment may be represented by single agent interferon, single agent interleukin-2 or a combination of interferon with interleukin-2 with or without accompanying hematological growth factors).

- Documented evidence of progressive disease in the previous 3 months. In the absence of radiographic studies, patients may be entered on the study if they have clinical evidence of progressive disease.

- Have at least one unidimensional measurable lesion of RCC according to the RECIST guidelines. The following will not qualify as measurable lesions: bone, leptomeningeal disease, ascites, pleural/pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed and followed by imaging techniques, and cystic lesions.

- Be ambulatory and have a Karnofsky performance status >=70%.

- Have a life expectancy of at least 3 months.

- Give written informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.

- Be willing and able to comply with the study protocol for the duration of the study.

Exclusion Criteria:

- Woman who are pregnant or breastfeeding. Women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate contraceptive measures (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).

- Fertile male subjects not willing to use contraception and whose female partners are not under adequate contraceptive protection.

- Known CNS metastases (if clinical suspicion of CNS metastases exists appropriate imaging must be performed prior to study entry).

- Prior treatment with chemotherapy (there is no restriction on prior epidermal growth factor directed therapy).

- Severe and uncontrolled cardiac or cardiovascular abnormalities.

- Severe uncontrolled intercurrent infections.

- Subjects with organ allografts.

- Any of the following abnormal screening hematological values: Hemoglobin (Hb) <9g /dL (6 mmol/L), Neutrophils <1.5 x 10^9/L, Platelets <100 x 10^9/L.

- Blood transfusions or growth factors to aid hematological recovery within 2 weeks prior to starting study treatment.

- Any of the following abnormal screening liver function tests: serum bilirubin >= 1.5 x upper normal limit (ULN), alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) >= 2.5 x ULN (unless related to liver metastases in which case >= 5 x ULN).

- The following abnormal screening renal function tests: either a serum creatinine > 1.5 x ULN or a creatinine clearance (estimated from serum creatinine) < 40 mL/minute.

- Prior radiotherapy (except palliative).

- Participation in any investigational drug study or immunotherapy within 4 weeks preceding treatment start.

- History of hypersensitivity to sulphonamides.

- Any concurrent or previous malignancy of a different tumor type within 5 years of starting E7070 treatment except for adequately treated non-melanoma skin cancer or cervical intra-epithelial neoplasia.

- Significant disease, which in the Investigator's opinion would exclude the patient from the study.

- Surgically resectable metastatic disease.

- Legal incapacity.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
E7070


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Eisai Inc.

Countries where clinical trial is conducted

United States,  France, 

See also
  Status Clinical Trial Phase
Completed NCT02248389 - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses Phase 1
Completed NCT03900364 - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A
Completed NCT00158782 - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients Phase 1
Completed NCT03109015 - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing Phase 2
Completed NCT00363194 - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients Phase 1
Completed NCT01012011 - Regulatory Post Marketing Surveillance Study on Nexavar® N/A
Completed NCT00842790 - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging N/A
Completed NCT00529802 - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer Phase 2
Completed NCT00338884 - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer Phase 2
Completed NCT00356460 - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma Phase 1
Completed NCT00387764 - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Phase 3
Completed NCT00095186 - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma Phase 2
Completed NCT00079612 - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer Phase 2
Completed NCT00043368 - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) Phase 2
Active, not recruiting NCT04489771 - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Phase 2
Completed NCT00516672 - Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors Phase 1
Withdrawn NCT05104905 - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma Phase 1/Phase 2
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT03111901 - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Phase 1/Phase 2
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1

External Links